{"denoms":[{"counts":[{"groupId":"BG000","value":"35"}],"units":"Participants"}],"groups":[{"description":"Induction:\n\nBortezomib (Velcade) 1.3 mg/m2/dose intravenous (IV) Days 1, 4, 8, 11 repeated every 21 days Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days\n\nConditioning:\n\nBortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4 Melphalan 70-100 mg/m2/day IV on days -2 and -1\n\nBortezomib (Velcade) and Dexamethasone: Induction:\n\nVelcade 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days\n\nDexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days\n\nConditioning:\n\nBortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4\n\nMelphalan 70-100 mg/m2/day IV on days -2 and -1","id":"BG000","title":"Bortezomib and Dexamethasone"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"30"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"22"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"13"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}